Page 76

Mayo_2017

comunicación breve 4. Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, et al. Reduced Treatment Intensity in Patients with Early-Stage Hodgkin`s Lymphoma. New England Journal of Medicine 2010; 363 (7): 640-52. 5. Wilder RB, Schlembach PJ, Jones D, Chronowski GM, Ha CS, Younes A, et al. European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, 622 lymphocyte-predominant Hodgkin disease. Cancer 2002; 94 (6): 1731-8. 6. von Tresckow B, Plutschow A, Fuchs M, Klimm B, Markova J, Lohri A, et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 2012; 30 (9): 907-13. 7. Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med 2015; 372 (17): 1598-607. 8. Raemaekers JM, Andre MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, et al. Omitting radiotherapy ABVD en linfoma de Hodgkin localizado - J. Díaz et al in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 2014; 32 (12): 1188-94. 9. Brice P. Managing relapsed and refractory Hodgkin lymphoma. Br J Haematol 2008; 141 (1): 3-13. 10. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012; 30 (18): 2183-9. 11. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32 (27): 3059-68. 12. Cabrera M, García H, Lois V, León A, Peña K, Rossle A, et al. Linfoma de Hodgkin en Chile. Experiencia de 15 años del Programa Nacional de Cáncer del Adulto. Rev Med Chile 2007; 135: 341-50. Rev Med Chile 2017; 145: 619-622


Mayo_2017
To see the actual publication please follow the link above